← boardnext 2029-09-30
TOVX
Theriva Biologics, Inc.distress 8/10 · high distress / dilution risk$0.23-2%today-73% from 52w high
Oncology 1
Lead: metastatic pancreatic ductal adenocarcinoma · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$14M
Runway
1.0 yrs
Shares 1y
+378%
Price & events
+7.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
-1.7%
1W
-9.6%
1M
-40.5%
3M
+13.0%
6M
-55.7%
1Y
-96.8%
2Y
-99.8%
5Y
-99.8%
All
Overview
- Market Cap
- $10.38M
- Enterprise Value
- $-2.38M
- Volume
- 115.03K
- 52 Week Range
- $0.18 – $0.84
- Total Shares
- 45.89M
- Float Shares
- 45.14M
- Short %
- 3.17%
- % Held by Insiders
- 1.63%
- % Held by Institutions
- 4.32%
- RVOL
- 0.01x
- Beta
- 1.09
Pipeline stages · 2 programs
SYN-004
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Nab-paclitaxel, Gemcitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-09-30 Estimated 50% readout ~2029-11-14 | Phase 1/2 | SYN-004 | Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics | — | active not recruiting |
| 2025-03-28 | Phase 2 | Nab-paclitaxel, Gemcitabine | Pancreatic Adenocarcinoma, Metastatic | 112 | completed |
Catalyst news & presentations · 10
- 2026-07-07fda agreementVCN-01 · AEMPS authorized initiation of VIRAGE2 Phase 2a trial.SEC 8-K
- first half of 2026regulatory submissionFiled (NDA/BLA)VCN-01 · End-of-Phase 2 meeting with FDA to finalize Phase 3 trial design.SEC 8-K
- Monday April 20, 2026, 2:00-5:00 PM US PDTconferencedata presentationsecondaryPhase 2VCN-01 · Poster presentation of VIRAGE Phase 2b trial data at AACR 2026SEC 8-K
- 2026-03-23fda agreementVCN-01 · FDA agreed with Phase 3 trial design including primary endpoint OS, key secondary PFS, adaptive design, and dosing regimen.SEC 8-K
- 2026-02-18partnershipSYN-020 · Exclusive worldwide license to develop and commercialize SYN-020SEC 8-K
- 2026-02-11enrollment delaySpecial meeting of stockholders could not convene due to lack of quorum; approval process delayed.SEC 8-K
- 2025-12-29fda agreementVCN-01 · CHMP agreed on Phase 3 trial design including primary endpoint overall survival, secondary endpoints, sample size, adaptive design, and repeated dosing macrocycles.SEC 8-K
- October 20, 2025conferencedata presentationsecondaryPhase 2VCN-01 · Expanded Phase 2b data presented at ESMO 2025SEC 8-K
- October 20, 2025conferencedata presentationsecondarySYN-004 · Interim blinded safety and pharmacokinetic dataSEC 8-K
- 2024-09-16partnershipVCN-01 · Award of €2.28 million from Spanish government for THERICEL project collaboration with UAB to advance suspension cell platform for clinical manufacture of adenovirus and AAV therapies.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-31Maxim GroupHold → Buy
- 2025-05-08Maxim GroupBuy → Hold
- 2024-11-13Maxim GroupBuy
Competitors — metastatic pancreatic ductal adenocarcinoma
- ABBVAbbVie Inc.$451.1B · D2
- NVSEFNOVARTIS AG$292.0B · D3
- RVMDRevolution Medicines, Inc.$40.3B · D1
- ERASErasca, Inc.$5.9B · D4
- RCUSArcus Biosciences, Inc.$3.8B · D5
- VSTMVerastem, Inc.$515M · D5
- AGENAGENUS INC$235M · D7
- ONCYONCOLYTICS BIOTECH INC$98M · D7
- ACTUACTUATE THERAPEUTICS, INC.$31M · D8
- LSTALISATA THERAPEUTICS, INC.$20M · D4
Recent news
- 2026-07-22Theriva Biologics (TOVX) Proxy Filing Summary - Quartr
- 2026-07-16Theriva Biologics (TOVX) Declines 5.6% as Stock Tests Key Support Levels - AI Trade Signals - dars.gov.et
- 2026-07-07Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - GlobeNewswire
- 2026-07-07Theriva Biologics cleared to start VIRAGE2 trial | TOVX 8-K Filing - Stock Titan
- 2026-07-07Theriva wins Spain nod for more frequent VCN-01 dosing in pancreatic cancer trial - Stock Titan
- 2026-07-07Theriva Biologics Gets Spain Approval for Phase 2a Trial of Pancreatic Cancer Therapy - marketscreener.com
- 2026-07-06Theriva Biologics (TOVX) Holds Steady Near Support After Modest Gain - Retracement Entry - dars.gov.et
- 2026-06-26TOVX Forecast — Price Target — Prediction for 2027 - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.